Introduction
Linezolid is an oxazolidinone used as an effective therapeutic option against vancomycin-resistance enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Linezolid resistance in staphylococci and enterococci have been reported, but not from India. [1] However, two reports from the Health Protection Agency provide evidence of transferable linezolid resistance in enterococci from a patient who received treatment in India. [2, 3] The most common cause of linezolid resistance in staphylococci and enterococci is due to a G2576U mutation in the 23S rRNA. Resistance may also be due to presence of a transferable plasmid-borne cfr Indian Journal of Medical Microbiology vol. 33, No. 1 hospitalisation at our institute he was given Linezolid 600 mg twice daily for seven days after incision and drainage of the abscess at another healthcare setup.
Microbiological investigations and susceptibility testing
Blood culture of the patient isolated pure growth of E. faecium. The isolate was subjected to antimicrobial susceptibility for ampicillin, chloramphenicol, erythromycin, vancomycin, linezolid, tetracycline, tigecycline and high level gentamicin [Hi-Media, India] by Kirby Bauer disc diffusion method. All breakpoint zones were interpreted as per Clinical and Laboratory Standards Institute breakpoints. [7] Minimal inhibitory concentrations (MIC) for vancomycin was determined by E-Test (AB BioMerieux, India). MIC's for linezolid were determined using the commercial PBP20 (positive breakpoint combo) panel of MicroScan Walkaway 96 Plus (Siemens, India) and GP67 (Gram positive) panel of Vitek 2 Compact (BioMerieux, India). Stool sample was collected and cultured on Mac Conkey medium [Hi -Media, India] to detect colonisation with Enterococcus, which also isolated linezolid resistant E. faecium. The patient was screened for carriage of MRSA from the anterior nares, axilla and groin. Swabs collected from these sites were cultured on mannitol salt agar [Hi -Media, India]. Sample from the nares isolated an MRSA strain, which was resistant to linezolid.
Conjugation studies
To demonstrate the presence of transferable resistance, conjugation experiments were performed. The LRVRE isolates from blood and LRMRSA from nares were used as donor strains. Eighteen tetracycline resistant clinical isolates of genus Enterococcus [E. faecium (4), E. fecalis (12) and E. raffi nosus (2)] and 10 tetracycline resistant S. aureus isolates were included as prospective recipients for linezolid resistance. All recipient strains used were wild clinical isolates. Fresh overnight growth of donor and recipient strains were mixed in a 1:10 ratio for broth mating experiments overnight in brain heart infusion (BHI) broth in presence and absence of sub-inhibitory concentrations of linezolid (≤0.25 mg/L) with intermittent shaking for upto 48 hours at 37°C in ambient air. [8] Sub-inhibitory concentration of linezolid was used to detect whether presence of the drug would act as a stimulus for possible transfer of resistance to susceptible wild recipients. Subcultures were made on 5% sheep blood agar containing 8 mg/L tetracycline and incubated for 24 hours to allow the growth of transconjugates. Pure growth of transconjugate was used to assess linezolid sensitivity by Kirby Bauer disc diffusion method as well as by the automated system (MicroScan Walkaway).
PCR and amplicon sequencing
DNA was extracted from fresh growth of the three isolates using the GeneiPureID DNA isolation kit (Merck, India). Control strains ATCC 29212 E. faecium and ATCC 25923 S. aureus were used as positive controls and ATCC 25922 Escherichia coli was used as negative control for the PTC region. Forward (5′-TAGTACCTGTGAAGATGCAGG-3') and reverse (5′-CACACTTAGATGCTTTCAGCG-3′) primers (Sigma, India) were used to amplify the 746-bp region of domain V of the 23S rRNA gene, which is the known hotspot harbouring the mutations responsible for linezolid resistance. [9] The PCR conditions were standardised at; heated lid at 112°C and initial denaturation at 95°C for 5 min, followed by 30 cycles consisting of denaturation at 95°C for one minute, annealing at 55°C for 30 seconds, extension at 72°C for one minute, and a fi nal extension step at 72°C for seven minutes. The 746-bp amplicon was purifi ed and direct sequencing was done on ABI 3730 DNA Analyser by using BigDye ® Terminator v3.1 Cycle Sequencing Kit from ABI (Hitachi, Applied Biosystems, Japan). The 23S rRNA reference sequences were BLAST searched on the National Center for Biotechnology Information (NCBI) database and compared with the obtained sequence on the SeqSequence ® software. Presence of a mutation was considered valid only if the quality value (QV) score for the site was >20 as generated by the software. [10] 
Results

Antimicrobial susceptibility testing
For the E. faecium isolate from blood, a decreased breakpoint zone for linezolid (18mm) was observed by disc diffusion. It was susceptible to tetracycline and tigecycline but resistant to all other antibiotics. Antibiogram pattern of E. faecium isolated from stool was identical to the blood isolate. MIC for vancomycin determined by E-test in both isolates was 94 mg/L. MIC breakpoints for linezolid in the PBP20 panel of Microscan walkaway 96 plus GP67 panel of Vitek 2 for both isolates were >4 and ≥8 mg/L. From anterior nares we isolated an MRSA strain with linezolid MIC > 8 mg/L detected by both the automated methods. This isolate was susceptible to vancomycin and tetracycline and resistant to all other drugs on the PBP20 and GP67 panels.
Conjugation studies
Among the 18 donor-recipient combinations in enterococci, only six exhibited growth on sheep blood agar with tetracycline (four E. fecalis and one each of E. faecium and E. raffi nosus) in the presence as well as absence of sub-inhibitory dose of linezolid while only four did so in S. aureus. Subsequent antimicrobial susceptibility testing demonstrated that all transconjugates were susceptible to linezolid by disc diffusion as well as the automated system indicating presence of non-transferable linezolid resistance to homologous or heterologous wild enterococci or S. aureus isolates.
PCR and sequencing
PCR produced an approximately 746-bp amplicon for Gram positive isolates as depicted in Figure 1 . Sequencing of the amplicon confi rmed the presence of the classical G2576U mutation on the 23S rRNA in the LRMRSA isolate from the nares [ Figure 2 ]. The QV scores for the forward and reverse sequences for this site were 44 and 56, respectively. Neither the classical G2576U mutation nor any other mutations were observed from positions 2017 to 2763 in either of the E. fecium isolates from blood and stool. [6] Detection of the cfr gene was not performed due to cost constraints. The forward segment of LRMRSA isolate was submitted in the BankIt facility of NCBI [BankIt1650323]. The GenBank accession number generated was KF 479352 and the isolate was labelled SA2606.
Discussion
Availability in an oral formulation has made linezolid an empirical outpatient drug in a country like India which has no stringent policies on antimicrobial prescribing practices. This is the fi rst formal report from India describing linezolid resistance in patient harbouring both, LRVRE and LRMRSA isolates. What is alarming in this case is the presence of linezolid resistance in strains isolatedfrom the infection as well as surveillance sites and death of the patient which may not be attributed totally to isolation of LRVRE from blood and failure of antimicrobial therapy given to the patient. The patient however should have been screened for presence or absence of these isolates prior to linezolid therapy. The role of the classical G2576U mutation in LRMRSA isolate could not be correlated clinically but we hypothesise that rapid development of linezolid resistance in S. aureus may have been due to presence of cryptic resistance in other alleles of the 23S rRNA PTC region. [11] This can be linked only if prior molecular and phenotypic screening for MRSA/VRE is performed before commencement of linezolid therapy. Sequencing of the LRVRE isolates also did not highlight any known or unknown mutations for linezolid resistance. It may be possible that cfr gene may have existed in these LRVRE isolates, and that the conjugations experiments may have failed to detect its transfer. More studies are required to prove the hypothesis of presence of cryptic resistance to linezolid. Presence of mutation in a single operon of multiple alleles of 23S rRNA may not exhibit phenotypic linezolid resistance and therefore it becomes imperative that such mutations with cryptic resistance need to be screened prior to linezolid therapy before development of frank resistance due to sequential mutations during therapy. [9, 11] This report cites the result of irrational use of antimicrobial agents highlighting importance of implementation of antibiotic prescription audits and hospital antibiotic policies. Presence of the classical G2576 mutation highlights excessive or inadequate exposure to linezolid, but its chromosomal location does not threaten rampant spread and such infections can be controlled by infection control practices. Contrarily, presence of the cfr gene, poses a much greater threat due to its location on a transferable plasmid and may cause rapid dissemination of linezolid resistance in enterococci. [11, 12] 
